Lexaria Bioscience Corp
Healthcare · USD
Price
$1.03
Cap
$26M
Earnings
3/4 beat
30d Trend
—
Lower half of range — may offer entry value
Target range: $1.5 – $6 (consensus: $1.5)
Consensus: Hold
Earnings history
Q1 2026
BEAT
-0.07 vs -0.13
Q4 2025
BEAT
-0.13 vs -0.16
Q3 2025
MISS
-0.21 vs -0.15
Q2 2025
BEAT
-0.15 vs -0.16
Key macro factors
Regulatory landscape for biotechnology and drug development, especially concerning novel drug delivery systems and specific therapeutic areas like GLP-1 drugs.
Trends in the pharmaceutical industry towards improved patient compliance and reduced side effects through advanced drug delivery technologies.
Access to capital markets and investor sentiment towards early-stage biotechnology companies, impacting Lexaria's ability to fund ongoing research and commercialization efforts.
Lexaria Bioscience Corp. is a biotechnology company that develops and licenses a patented oral drug delivery formulation and processing platform known as DehydraTECH™.
QUANT SCORE
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.